Dr. Lieu joined the University of Colorado School of Medicine
faculty as an Assistant Professor in July 2011.
He trained in internal medicine at the University of Colorado, where he
also served as a Chief Medical Resident.
He completed his fellowship training in medical oncology at the
University of Texas MD Anderson Cancer Center and served as the Chief Medical
Oncology Fellow in 2010.
Dr. Lieu is a member of the Developmental Therapeutics (phase
I clinical trials) and Gastrointestinal (GI) Medical Oncology Program. These comprehensive programs include
multidisciplinary cancer clinics, tumor boards, and research endeavors. Dr. Lieu is interested in resistance
mechanisms to targeted therapy in GI cancers, and he was awarded the Conquer
Cancer Foundation Career Development Award and a NIH K23 grant to study targeted
therapies in colorectal cancer.
Honors and Awards
P. Gold Foundation Excellence in Humanism and Teaching Award
-Ruth L. Kirschstein National
Research Service Award
-American Society of Clinical
Oncology (ASCO) Young Investigators Award
-Conquer Cancer Foundation Merit Award
-Paul Calabresi Career Development Award for
Clinical Oncology (K12)
-Delegate, ASCO/AACR Methods in Clinical Cancer
-SWOG Young Investigator Award
-ASCO Conquer Cancer Foundation Career
-Department of Internal Medicine Rising Stars
1. Lieu C, Anderson R. Serum creatinine: Why lower may not
be better. Crit Care Med 2007; 35(10):2458-9. PMID: 17885392
2. Lieu C, Janssen WJ, Saint S,
Dhaliwal G. The tip of the iceberg. J Hosp Med
2009; 4(5):317-20. PMID: 19504498
3. O’Bryant C, Lieu C**, Leong S, Boinpally R, Basche M, Gore L,
Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A
dose-ranging study of the pharmacokinetics and pharmacodynamics of the
selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with
advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol
2009; 63(3):477-89. PMID: 18509645
4. Lieu C, Chow L, Pierson A, Eckhardt SG, O’Bryant CL,
Morrow M, Tran ZV, Wright JJ, Gore L. A phase I study of bortezomib, etoposide
and carboplatin in patients with advanced solid tumors refractory to standard
therapy. Invest New Drugs 2009; 27(1):53-62. PMID: 18618082
5. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Adinin R, Overman MJ,
Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis L, Abbruzzese JL, Heymach
JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab
for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic
Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 2010;
28(3):453-9. PMID: 20008624
6. Lieu C, Kopetz S. Src family of protein kinases: a
new and promising target for colorectal cancer. Clin Colorectal Cancer
2010; 9(2):89-94. PMID: 20378502
7. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A,
Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite
instability on the pattern of metastatic spread and prognosis in metastatic
colorectal cancer. Cancer 2011: 117(20):4623-32. PMID: 21456008
8. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S,
Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ.
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and
signet ring cell adenocarcinomas of the appendix. Ann Oncol 2011;
23(3): 652-8. PMID: 21653683
9. Lieu CH, Heymach JV, Overman MJ, Tran H, Kopetz S.
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and
Antiangiogenesis. Clin Cancer Res 2011; 17(19): 6130-9.
10. Scott AJ, Leong S, Messersmith WA, Lieu CH. A Moving
Target: challenges in treating BRAF-mutant colorectal cancer. Colorectal
Cancer 2013; 2(3): 197-204.
11. Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG.
From Bench to Bedside: Examples of lessons learned in the translation of
preclinical studies of targeted agents in cancer drug development. J
Nat Cancer Inst 2013; doi: 10.1093/jnci/djt209. PMID: 24052618
12. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng
C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate
VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal
cancer. PLOS ONE 2013; 8(10):e77117. PMID: 24143206
Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS,
Seymour MT, Goldberg RM, Sargent D, Eckhardt SG, Eng, C. The association of age with survival in
patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical
Trials Program. J Clin Oncol 2014; doi:10.1200/JCO.2013.54.9329.
14. Brittain P, Eckhardt SG, Lieu CH.
Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer. Current Cancer Therapy Reviews 2014;
15. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Quao W, Morris J,
Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance
of high neutrophil-lymphocyte ratio in colorectal cancer. Br J
Cancer 2015; doi. 10.1038/bjc.2015.61 [epub ahead of print]. PMID 25688736.
** - co-first author
K12 Paul Calabresi Career Development Award for Clinical Oncology
Cancer Foundation Young Investigators Award
Cancer Foundation Career Development Award
Cancer League of
Colorado Research Award
Foundation SWOG Early Exploration and Development (SEED) Award